11 / 32
•
The investigators concluded that
stromal TILs have prognostic value
for patients with ovarian cancer
both pre- and post- neoadjuvant
chemotherapy.
Cohort profile: African Collaborative
Center for Microbiome and Genomics
Research (ACCME) study.
SN Adebamowo,
E Dareng, A Famooto, et al
•
This multicentre prospective cohort
study has enrolled 10,300 women
in Nigeria to examine associations
between cervical cancer and several
relevant parameters, including
genomics, epigenomics, HPV
genotype, cervical cytokines, vaginal
pH, and the vaginal microenvironment.
At baseline, the mean age of the study
participants was 40 years, 76% of the
participants were married, and 30% of the
participants were HPV-positive.
•
The trial withmore than 10,000 participants
offers new opportunities of translational
research in biomarker discovery that
addresses high-impact public health
challenges affecting women’s health in
third-world countries
Phase II study of anastrozole in recurrent
estrogen/progesterone-positive endometrial
cancer: The PARAGON trial – ANZGOG 0903.
LR Mileshkin, RJ Edmondson, R O’Connell, et al
•
In an open-label arm of the phase 2
PARAGON trial, investigators assessed the
effect of anastrozole on quality of life (QOL)
in patients with ER/PR-positive metastatic
hormone-naive endometrial cancer. At 3
months, the clinical benefit rate in patients
treated with anastrozole was 44% (95%
CI, 34–55%). Compared with patients
who progressed on therapy, those who
achieved clinical benefit also had significant
improvements in QOL domains, including
emotional functioning (39 vs 6%; P = 0.002),
cognitive functioning (45 vs 19%; P = 0.021),
fatigue (47 vs 19%; P = 0.015) and global
health status (42 vs 9%; P = 0.003).
•
Anastrozole provided a significant clinical
benefit, which was associated with
improved QoL, in patients with ER/PR-
positive endometrial cancer.
Less versus more radical surgery in stage IB1
cervical cancer: A population-based study of
long-term survival.
MM Leitao, Y Sonoda, GJ
Gardner, et al
•
In this retrospective study, the 10-year
disease-specific survival (DSS) rate was
evaluated in 2838 young (< 45 years of age)
women with stage IB1 cervical cancer who
had been treated with less radical surgery
or more radical surgery. Less radical surgery
© ASCO/Todd Buchanan 2016
was defined as conization, trachelectomy, or
simple hysterectomy; more radical surgery
was defined as modified radical or radical
hysterectomy. The researchers found no
significant difference in the 10-year DSS
rate between less and more radical surgery
(92.8 ± 0.1% vs 92.3 ± 0.7%; P = 0.80) for all
tumours, or for tumours stratified according
to size. Neither approach was independently
associated with the10-year DSS rate.
•
The conclusions reached are that less
radical surgery does not appear to
compromise 10-year DSS in patients with
stage IB1 cervical cancer.
Use of next-generation sequencing panels to
predict recurrence in low-grade, early-stage
endometrioid endometrial carcinoma.
K Kurnit,
B Fellman, DL Urbauer, et al
•
In this retrospective study, next-generation
sequencing was used to profile samples
from patients with low-grade, early-stage
endometrioid endometrial cancer to identify
variables associated with recurrence-free
survival (RFS). Mutations in CTNNB1 and
TP53 were associated with reduced rates
of RFS (HR ,4.65; 95% CI, 2.33–9.30;
P < 0.001).
•
Mutations in CTNNB1 and TP53 are
independent predictors of poor RFS
in patients with low-grade, early-stage
endometrioid endometrial cancer.
Impact of body mass index on surgical costs
and morbidity for women with endometrial
carcinoma/hyperplasia.
RS Suidan, W He, CC
Sun, et al
•
Investigators assessed whether body mass
index (BMI) affected surgical complications
and costs in 1112 patients with endometrial
cancer and endometrial hyperplasia.
Patients with BMI
≥
40 had a higher rate
of wound infection following laparotomy
compared with patients with BMI 30–39
or BMI
≤
29 (14% vs 5% vs 5%; P < 0.01).
These patients also experienced a higher
rate of thromboembolic complications (3%
vs 0.2% vs 0.3%; P < 0.01). The rates of
wound infections and thromboembolic
complications were not increased in patients
with BMI
≥
40 who underwent minimally
invasive surgery. Other complications and
median 30-day costs were not significantly
different among the three BMI groups.
However, median costs were higher for
patients with complications.
•
Minimally invasive surgery may reduce costs
and minimise complications in patients with
endometrial cancer and BMI
≥
40.
Prognosis after local recurrence in vulvar cancer:
A subset analysis of the AGO-CaRE-1 study.
LL
Woelber, C Eulenburg, J Kosse, et al
•
In this subgroup analysis of the retrospective
AGO CaRE-1 study, investigators
evaluated the rate of cancer recurrence in
1249 patients with primary squamous cell
vulvar cancer. Following a median of 39.4
months, disease had recurred in 28.8%
of the patients. In the 53.6% of patients
with recurrent disease who suffered
vulvar recurrence, nodal involvement was
a negative prognostic factor (HR, 2.47;
95% CI, 1.52–4.03) and complete tumour
resection was a positive prognostic factor
(HR, 0.33; 95% CI, 0.17–0.63). Over the
course of the study, a second recurrence
developed in 30.1% of patients with a
vulvar recurrence.
•
The investigators concluded that the
prognosis for patients with isolated vulvar
recurrence is worse than previously
appreciated.
ASCO 2016
11
DECEMBER 2016